Beam Therapeutics Inc.

BEAM Nasdaq CIK: 0001745999

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Mailing Address 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Phone 857-327-8775
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

$370.28M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 1, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
8-K Current report of material events March 5, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
8-K Current report of material events February 24, 2026 View on SEC
10-K Annual financial report February 24, 2026 View on SEC
8-K Current report of material events February 12, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 9, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 5, 2026 View on SEC

Material Events

8-K Acquisition December 11, 2025
High Impact
  • Beam Therapeutics sold its ownership stake in Orbital Therapeutics, Inc.
  • The sale occurred as part of Bristol-Myers Squibb's acquisition of Orbital Therapeutics.
View Analysis

Insider Trading

STRONG SELL 5 insiders 15 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.